Pancreatic Cancer Research

ResearcherUtrecht UniversityActive in the last 2 years

Steffi J. E. Rombouts

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5109499487. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2015: 1 paper · 2016: 3 papers · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 10

  1. Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. Co-author DOI 10.1001/jamanetworkopen.2026.3861↗
  2. Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. Co-author DOI 10.1016/j.ejso.2020.11.137↗
  3. Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled… Co-author DOI 10.1186/s13063-021-05248-y↗
  4. Computed tomography findings after radiofrequency ablation in locally advanced pancreatic cancer. Co-author DOI 10.1007/s00261-018-1519-y↗
  5. Systematic review on the treatment of isolated local recurrence of pancreatic cancer after surgery; re-resection, chemoradiotherapy and SBRT. Co-author DOI 10.1016/j.hpb.2016.11.001↗
  6. Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. First author DOI 10.1245/s10434-017-5900-9↗
  7. Recent Advances in Pancreatic Cancer Surgery of Relevance to the Practicing Pathologist. First author DOI 10.1016/j.path.2016.05.002↗
  8. Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-016-5373-2↗
  9. FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Cancer: A Single Centre Cohort Study. Co-author DOI 10.7150/jca.16279↗
  10. Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer. Co-author DOI 10.1002/bjs.9716↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Izaak Quintus Molenaar · 8 shared papers, 2015–2021 · strength 0.54
  2. Marc G. Besselink · 8 shared papers, 2015–2021 · strength 0.52
  3. Hjalmar C. van Santvoort · 6 shared papers, 2015–2021 · strength 0.43
  4. Marieke S. Walma · 5 shared papers, 2016–2021 · strength 0.36
  5. Johanna W. Wilmink · 5 shared papers, 2016–2021 · strength 0.34
  6. Krijn P. van Lienden · 4 shared papers, 2015–2021 · strength 0.27
  7. Maarten Simon van Leeuwen · 3 shared papers, 2018–2021 · strength 0.25
  8. Jantien A. Vogel · 4 shared papers, 2015–2017 · strength 0.23
  9. Nadia Haj Mohammad · 3 shared papers, 2016–2021 · strength 0.22
  10. Richard van Hillegersberg · 3 shared papers, 2015–2021 · strength 0.22
  11. Freek D. Daams · 2 shared papers, 2021 · strength 0.16
  12. Gijs A. Patijn · 2 shared papers, 2021 · strength 0.16
  13. Martijn Ruben Meijerink · 2 shared papers, 2021 · strength 0.16
  14. Vincent Erwin de Meijer · 2 shared papers, 2021 · strength 0.16
  15. Sebastiaan Festen · 2 shared papers, 2021 · strength 0.16
  16. Lilly J. H. Brada · 2 shared papers, 2021 · strength 0.16
  17. Judith de Vos‐Geelen · 2 shared papers, 2021 · strength 0.16
  18. Ignace H. J. T. de Hingh · 2 shared papers, 2021 · strength 0.16
  19. Martijn W.J. Stommel · 2 shared papers, 2021 · strength 0.16
  20. Hanneke W.M. van Laarhoven · 2 shared papers, 2016–2017 · strength 0.12
  21. L. Bengt van Rijssen · 2 shared papers, 2016 · strength 0.11
  22. Thijs J. Schouten · 1 shared paper, 2021 · strength 0.08
  23. John J. Hermans · 1 shared paper, 2021 · strength 0.08
  24. Geert‐Jan Creemers · 1 shared paper, 2021 · strength 0.08
  25. Poya Ghorbani · 1 shared paper, 2021 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.